These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 18601950

  • 1. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T, Pollard C, Sager P.
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [Abstract] [Full Text] [Related]

  • 2. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK, Hancox JC, Curtis MJ.
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [Abstract] [Full Text] [Related]

  • 3. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA.
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [Abstract] [Full Text] [Related]

  • 4. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
    Carlsson L.
    Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435
    [Abstract] [Full Text] [Related]

  • 5. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
    Wang D, Patel C, Cui C, Yan GX.
    Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
    [Abstract] [Full Text] [Related]

  • 6. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC, McPate MJ, El Harchi A, Zhang YH.
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [Abstract] [Full Text] [Related]

  • 7. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Aug; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 8. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL, Kung MF.
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [Abstract] [Full Text] [Related]

  • 9. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N, Authier S, Pugsley MK, Curtis MJ.
    Toxicol Appl Pharmacol; 2010 Mar 01; 243(2):146-53. PubMed ID: 20005885
    [Abstract] [Full Text] [Related]

  • 10. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K.
    Pharmacol Ther; 2008 Aug 01; 119(2):195-8. PubMed ID: 18486227
    [Abstract] [Full Text] [Related]

  • 11. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y, Mashav N, Henis O, Swartzon M, Arbel Y, Justo D.
    Anadolu Kardiyol Derg; 2008 Aug 01; 8(4):260-5. PubMed ID: 18676301
    [Abstract] [Full Text] [Related]

  • 12. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ, Johnson DM, Weltens E, Lissens J.
    J Pharmacol Toxicol Methods; 2012 Sep 01; 66(2):125-34. PubMed ID: 22516473
    [Abstract] [Full Text] [Related]

  • 13. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, Ferenidou F, Mashav N, Sadeh B, Atzmony L, Kliuk-Ben-Basat O, Steinvil A, Justo D.
    J Electrocardiol; 2009 Sep 01; 42(4):353-357.e1. PubMed ID: 19261294
    [Abstract] [Full Text] [Related]

  • 14. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
    Thomsen MB, Matz J, Volders PG, Vos MA.
    Pharmacol Ther; 2006 Oct 01; 112(1):150-70. PubMed ID: 16714061
    [Abstract] [Full Text] [Related]

  • 15. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
    Webster R, Leishman D, Walker D.
    Curr Opin Drug Discov Devel; 2002 Jan 01; 5(1):116-26. PubMed ID: 11865665
    [Abstract] [Full Text] [Related]

  • 16. Drug-induced q-T prolongation.
    Kao LW, Furbee RB.
    Med Clin North Am; 2005 Nov 01; 89(6):1125-44, x. PubMed ID: 16227057
    [Abstract] [Full Text] [Related]

  • 17. Moxifloxacin-induced torsades de pointes.
    Sherazi S, DiSalle M, Daubert JP, Shah AH.
    Cardiol J; 2008 Nov 01; 15(1):71-3. PubMed ID: 18651388
    [Abstract] [Full Text] [Related]

  • 18. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
    Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, Oliver WC, Narr BJ, Ackerman MJ.
    Anesthesiology; 2007 Oct 01; 107(4):531-6. PubMed ID: 17893447
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?
    Shah RR.
    J Electrocardiol; 2005 Jan 01; 38(1):10-8. PubMed ID: 15660342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.